Infectious Disease Daily Report: 01/23/2024

A phase 3 randomized, double-blind study (NCT04875533) in Japan, South Korea, and Taiwan investigated the safety and immunogenicity of the 20-valent pneumococcal conjugate vaccine (PCV20) in 1421 participants ≥ 60 years of age (1). PCV20 was noninferior to PCV13 for all 13 matched serotypes and to PPSV23 for 6 of 7 additional serotypes. Although statistical noninferiority was missed for serotype 8, secondary immunogenicity endpoints were supportive of a robust immune response. The incidence of adverse events and the frequency and severity of local reactions and systemic events were generally similar after PCV20 and PCV13, with no safety concerns identified.

Reference

Haranaka M, Young Song J, Huang KC, de Solom R, Yamaji M, McElwee K, Kline M, Aizawa M, Peng Y, Scully I, Kogawara O, Gruber WC, Scott DA, Watson W. A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan. Vaccine. 2024 Jan 23:S0264-410X(24)00008-2. doi: 10.1016/j.vaccine.2024.01.004. Epub ahead of print. PMID: 38267330.